Locatelli, Franco
Whitlock, James A.
Peters, Christina http://orcid.org/0000-0003-0369-8515
Chen-Santel, Christiane
Chia, Victoria
Dennis, Robyn M.
Heym, Kenneth M.
Katz, Aaron J.
Kelsh, Michael A.
Sposto, Richard
Tu, Huakang
Tuglus, Catherine A.
Verma, Anupam
Vinti, Luciana
Wilkes, Jennifer J.
Zubarovskaja, Nathalya
Zugmaier, Gerhard
von Stackelberg, Arend
Sun, Weili
Funding for this research was provided by:
Amgen (Europe) GmbH
Article History
Received: 6 September 2019
Revised: 16 January 2020
Accepted: 12 February 2020
First Online: 24 February 2020
Compliance with ethical standards
:
: FL received consulting fees from Jazz Pharmaceuticals, Amgen, Bellicum, Miltenyi, BluebirdBio, and Novartis, and is on the speakers’ bureau for Jazz Pharmaceuticals, Amgen, Bellicum, Miltenyi, BluebirdBio, and Novartis. VC, HT, GZ, and CAT are employed by, and are stockholders of, Amgen Inc. AJK received Consulting fees from Kite, a Gilead company, and was a past employee and stockholder of Amgen shares during the initiation and conduction of study but not in the past 12 months. MAK is employed by, and is a stockholder of, Amgen. CP received consulting fees from Amgen, Novartis, and Medac, and is on the speakers’ bureau for Amgen, Novartis, Pfizer, Riemser, and Medac. AvS received consulting fees from Amgen, Novartis, Servier, and Morphosys, and is on the speakers’ bureau for Amgen and Servier. JAW received a research grant from Novartis and Consulting fees from Shire Pharmaceuticals. CC-S, RMD, KMH, AV, LV, RS, JJW, NZ, and WS declare that they have no conflict of interest.
: The current manuscript describes two analytical approaches using data from the blinatumomab phase 1/2 study, which is available on a publicly registered site-clinicaltrails.gov (NCT01471782) and which has been previously published [CitationRef removed]. The blinatumomab phase 1/2 study was formally approved by Innovative Therapies for Children with Cancer. This manuscript also uses data from the Therapeutic Advances in Childhood Leukemia and Lymphoma study which has previously been published [CitationRef removed]. This study was approved by the institutional review board of each participating institution. In both studies, the patients’ legal representatives gave written informed consent.